eIF2B Modulators for Integrated Stress Response

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies fail to effectively modulate the integrated stress response (ISR) pathway, particularly in addressing diseases related to eIF2α phosphorylation and eIF2B activity, which are implicated in neurodegenerative, inflammatory, and metabolic disorders.

Innovation Solution

Development of compounds, such as those represented by Formula (I), which act as eIF2B modulators to activate eIF2B and attenuate the ISR signaling pathway, thereby treating diseases like neurodegenerative disorders, leukodystrophies, cancers, and metabolic diseases by influencing eIF2α phosphorylation and ISR activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If eIF2α is phosphorylated in response to stress signals, then cellular stress response is activated, but translation initiation is inhibited and cellular function is impaired

Engineering Contradiction:

Improvestress response activationVSAvoidtranslation initiation

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent uses eIF2B activators as intermediary molecules that mediate between the stress signal and the translation initiation process. These compounds bind to eIF2B and enhance its GEF activity, allowing the stress response to be activated while maintaining translation initiation capability. The intermediary compound bridges the conflict between stress signaling and protein synthesis.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the activity parameter of eIF2B by introducing small molecule activators that increase its guanine nucleotide exchange factor activity. This parameter change allows phosphorylated eIF2α to be present (maintaining stress response) while eIF2B activity is enhanced enough to sustain translation initiation. The parameter of eIF2B activity is adjusted to resolve the contradiction.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If eIF2B activity is enhanced to maintain translation, then cellular productivity is improved, but sensitivity to eIF2α phosphorylation effects is reduced

Engineering Contradiction:

Improvetranslation initiationVSAvoidstress response sensitivity

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies partial action by enhancing eIF2B activity to a degree that is sufficient to maintain translation initiation but not so excessive that it completely abolishes stress response sensitivity. The eIF2B activators provide a partial enhancement that resolves the contradiction by maintaining enough sensitivity for stress detection while ensuring sufficient translation productivity.

Inventive Principle:

Principle #16Partial or excessive action

3Adaptability or versatility

If small molecule eIF2B activators are developed, then therapeutic treatment options are expanded, but drug development complexity increases

Engineering Contradiction:

Improvetherapeutic application rangeVSAvoiddrug development process

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent achieves universality by developing eIF2B activators that can treat multiple disease types (neurodegenerative diseases, metabolic disorders, inflammatory conditions) through a common mechanism of action. This multi-functionality expands therapeutic applications while the core chemical structure and mechanism remain consistent, managing development complexity through a unified approach.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20240000792A1Modulators of the integrated stress pathway

Publication Date: 2024.01.04 CALICO LIFE SCI LLC

AI summary

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.